Targeted therapies for soft-tissue sarcomas

Expert Review of Anticancer Therapy

Volumn 7, Issue 5, 2007, Pages 725-733

  Tap, William D ^a   Federman, Noah ^a   Eilber, Fritz C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Apoptosis; Cell cycle; Fusion protein; Heat shock protein; Histone deacetylase; mTOR pathway; Soft tissue sarcoma; Telomerase; WNT signaling

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AP 23573; ARQ 501; BETA LAPACHONE; BEVACIZUMAB; CANCER VACCINE; CYCLIN B1; DOCETAXEL; DOXORUBICIN; FLAVOPIRIDOL; GEMCITABINE; HEAT SHOCK PROTEIN 90; IFOSFAMIDE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY FZD10; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SEMAXANIB; SMALL INTERFERING RNA; STA 4783; STEM CELL FACTOR RECEPTOR; TAXANE DERIVATIVE; TEMSIROLIMUS; TRANSCRIPTION FACTOR E2F1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; HEAT SHOCK PROTEIN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; RAPAMYCIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; CARDIOTOXICITY; CHORDOMA; CLINICAL TRIAL; DERMATOFIBROSARCOMA PROTUBERANS; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KAPOSI SARCOMA; LEIOMYOSARCOMA; MULTIMODALITY CANCER THERAPY; NONHUMAN; REVIEW; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TREATMENT OUTCOME; TUMOR LOCALIZATION; UNSPECIFIED SIDE EFFECT; APOPTOSIS; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; SARCOMA; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HEAT-SHOCK PROTEINS; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SARCOMA; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 34248578621     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.5.725     Document Type: Review

References (57)

1. Jemal A, Siegel R, Ward E et al. Cancer Statistics, 2006. CA Cancer J. Clin. 56, 106-130 (2006).
2. Eilber FC, Brennan MF, Eilber FR et al. Validation of the postoperative nomogram for 12-year sarcoma specific death. Cancer 101(10), 2270-2275 (2004).
3. Eilber FC, Rosen G, Nelson SD et al. High-grade extremity soft tissue sarcomas factors predictive of local recurrence and its effect on morbidity and mortality. Ann. Surg. 237(2), 218-226 (2003).
4. Borden EC, Baker LH, Bell RS et al. Soft tissue sarcomas of adults: state of the translational science. Clin. Cancer Res. 9, 1941-1956 (2003).
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100, 57-70 (2000).
6. Ohanna M, Sobering AK, Lapointe T et al. Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat. Cell Biol. 7(3), 286-294 (2005).
7. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 6(9), 729-734 (2006).
8. Okuno SH, Mahoney MR, Bailey HH et al. A multicenter Phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS). J. Clin. Oncol. 24(S18), 9504 (2006).
9. Chawla SP, Tolcher AW, Staddon AP et al. Updated results of a Phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. J. Clin. Oncol. 24(S18), 9505 (2006).
10. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18(1), 4-25 (1997).
11. Hu M, Nicolson GL, Trent JC et al. Characterization of 11 human sarcoma cell strains: evaluation of cytogenetics, tumorigenicity, metastasis, and production of angiogenic factors. Cancer 95(7), 1569-1576 (2002).
12. Graeven U, Andre N, Achilles E et al. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. J. Cancer Res. Clin. Oncol. 125(10), 577-581 (1999).
13. Kuhnen C, Lehnhardt M, Tolnay E et al. Patterns of expression and secretion of vascular endothelial growth factor in malignant soft-tissue tumours. J. Cancer Res. Clin. Oncol. 126(4), 219-225 (2000).
14. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(6423), 841-844 (1993).
15. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65, 671-680 (2005).
16. Kuenen BC, Tabernero J, Baselga J et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin. Cancer Res. 9, 1648-1655 (2003).
17. Heymach JV, Desai J, Manola J et al. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin. Cancer Res. 10, 5732-5740 (2004).
18. Gasparini G, Longo R, Fanelli M et al. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J. Clin. Oncol. 23(6), 1295-1311 (2005).
19. D'Adamo DR, Anderson SE, Albritton K et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J. Clin. Oncol. 23(28), 7135-7142 (2005).
20. Yoo J, Park SY, Kang SJ et al. Altered expression of G1 regulatory proteins in human soft tissue sarcomas. Arch. Pathol. Lab. Med. 26(5), 567-573 (2002).
21. Carlson BA, Dubay MM, Sausville EA et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 56(13), 2973-2978 (1996).
22. Motwani M, Li X, Schwartz G. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells. Clin. Cancer Res. 6, 924-932 (2000).
23. Morris DG, Bramwell VHC, Turcotte R et al. A Phase II study of flavopiridol in patients with previously untreated advanced soft tissue sarcoma. Sarcoma 2006, 1-7 (2006).
24. Li W, Fan J, Bertino JR. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity. Cancer Res. 61(6), 2579-2582 (2001).
25. D'Adamo DR, Scheu K, Singer S et al. A Phase I trial of doxorubicin and flavopiridol in soft tissue sarcoma. J. Clin. Oncol. 24(S18), 9523 (2006).
26. Chen Z, Xia Z, Gu WZ et al. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int. J. Cancer 119(12), 2784-2794 (2006).
27. Perez RP, Lewis LD, Beelen AP et al. Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). Clin. Cancer Res. 12(23), 7079-7085 (2006).
28. Li Y, Sun X, LaMont JT et al. Selective killing of cancer cells by β-lapachone: direct checkpoint activation as a strategy against cancer. Proc. Natl Acad. Sci. 100(5), 2674-2678 (2003).
29. Li C, Nemunaitis J, Senzer N et al. A Phase Ib trial of ARQ 501, a selective checkpoint activator, in combination with docetaxel in patients with advanced solid tumors. J. Clin. Oncol. 24(S18), 13053 (2006).
30. Hymowitz SG, Christmyer HW, Fuh G et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol. Cell 4(4), 563-571 (1999).
31. Herbst RS, Mendolson DS, Ebbinghaus S et al. A Phase I safety and pharmacokinetic (PK) study of recombinant. Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. J. Clin. Oncol. 24(S18), 3013 (2006).
32. Schmitt E, Gehrmann M, Brunet M et al. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J. Leuk. Biol. 81(1), 15-27 (2007).
33. Terry J, Lubieniecka JM, Kwan W et al. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models. Clin. Cancer Res. 11(15), 5631-5638 (2005).
34. Sherman ML, Ryan C, Blackstein M et al. Phase 1/2 study of STA-4783, a novel heat shock protein 70 (hsp70) inducer, in combination with paclitaxel in patient with soft tissue sarcomas (STS). J. Clin. Oncol. 23(S16), 9069 (2005).
35. Brujin D, Nap JF, Kessel AG. The (epi)genetics of human synovial sarcoma. Gene Chrom. Cancer 46, 107-117 (2007).
36. Kawaguchi S, Wada T, Ida K et al. Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J. Transl. Med. 3(1), 1 (2005).
37. Xie Y, Tornkvist M, Aalto Y. Gene expression profile by blocking the SYT-SSX fusion gene in synovial sarcoma cells. Identification of XRCC4 as a putative SYT-SSX target gene. Oncogene 22, 7628-7631 (2003).
38. Nagayama S, Fukukawa C, Katagiri T et al. Therapeutic potential of antibodies against FZD10, a cell surface protein, for synovial sarcomas. Oncogene 24, 6201-6212 (2005).
39. Kondapalli L, Soltani K, Lacouture ME. The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies. J. Am. Acad. Dermatol. 53, 291-302 (2005).
40. McArthur GA, Demetri GD, Oosterom A et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225. J. Clin. Oncol. 23, 866-873 (2005).
41. Casali PG, Messina A, Stacchiotti S et al. Imatinib mesylate in chordoma. Cancer 101(9), 2086-2097 (2004).
42. Casali PG, Stacchiotti S, Messina A et al. Imatinib mesylate in 18 advanced chordoma patients. J. Clin. Oncol. 23(S16), 9012 (2005).
43. Goy BW, Lee SP, Eilber F et al. The role of adjuvant radiotherapy in the treatment of resectable desmoid tumors. Int. J. Radiat. Oncol. Biol. Phys. 39(3), 659-665 (1997).
44. Goy BW, Lee SP, Fu YS et al. Treatment results of unresected or partially resected desmoid tumors. Am. J. Clin. Oncol. 21(6), 584-590 (1998).
45. Heinrich MC, McArthur GA, Demetri GD et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J. Clin. Oncol. 24(7), 1195-1203 (2006).
46. Evilevitch V, Weber W, Tap W et al. Change in quantitative FDG-PET was significantly more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high grade soft tissue sarcomas. Presented at: Am. Soc. Clin. Oncol. Chicago, IL, USA 1-5 June, 2007.
47. Ventura A, Kirsch DG, McLaughlin ME et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661-665 (2007).
48. Shay JW, Wright WE. Telomerase therapeutics for cancer: challenges and new directions. Nat. Rev. Drug Disc. 5(7), 577-584 (2006).
49. Gallinari P, Di Marco S, Jones P et al. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res. 17, 195-211 (2007).
50. Fuji N, You L, Xu Z et al. An antagonist of dishevelled protein-protein interaction suppresses β-catenin-dependent tumor cell growth. Cancer Res. 67(2), 573-579 (2007).
51. Haluska P, Carboni JM, Loegering DA et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I /insulin receptor inhibitor, BMS-554417. Cancer Res. 66(1), 362-371 (2006).
52. Shor AS, Keschman EA, Lee FY et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival. Cancer Res. 67(6), 2800-2808 (2007).
53. Ying H, Biroc SL, Li W et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol. Cancer Ther. 5(9), 2158-2164 (2006).
54. Toub N, Bertrand JR, Tamaddon A et al. Efficacy of siRNA nanocapsules targeted against the EWS-FLI1 oncogene in Ewing sarcoma. Pharm. Res. 23(5), 892-900 (2006).
55. Bernasconi M, Remppis, Fredericks WJ et al. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc. Natl Acad. Sci. USA 93(23), 13164-13169 (1996).
56. Chansky HA, Barahmand-Pour F, Mei Q et al. Targeting of EWS/FLI-1 RNA intererference attenuates tumor phenotype of Ewing's sarcoma cells in vitro. J. Orthop. Res. 22(4), 910-917 (2004).
57. Dohjima T, Lee NS, Li H et al. Small interfering RNAs expressed from a Pol II promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line. Mol. Ther. 7(6), 811-816 (2003).